AzTrials
AzTrials

Pain, PostoperativePhase 4NCT02299908

Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial

A Phase 4 study testing TAP block with Bupivacaine at 0.25% in people with Pain, Postoperative, run by Patricia Salazar Villegas at 2 sites in Colombia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Acute postoperative pain is one of the most important centers of therapeutic attention in postoperative phase of any procedure. It is a complex entity that requires a multiple intervention to be treated and, depending on the intervened surgical site, it has different approaches. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pain, Postoperative
What is being tested?
TAP block with Bupivacaine at 0.25%
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
2 sitesColombia
Study dates
Nov 2014to Oct 2015
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients over 18 years attending Servicios Especiales de Salud (SES) Hospital of Caldas and Santa Sofia Hospital for inguinal hernia surgery.
  • Physical status classification of the American Society of Anesthesiologists (ASA) (ASA I: healthy patient with no history or comorbidity and ASA II patients with compensated systemic disease).
  • Acceptance to complete the informed consent.

Who cannot join

  • Bilateral inguinal hernia.
  • Allergy to drugs used in the study protocol (propofol, remifentanil, dipyrone, Dexamethasone, Tramadol, Morphine, Bupivacaine, Cephalexin, Cefazolin, Lidocaine, Sevoflurane, Chlorhexidine, Adrenaline, Naproxen, Acetaminophen)
  • Lack of communication with the patient
  • Inadequate social support network and interaction with the physician.
  • Spinal Anesthesia
  • Herniorrhaphy without mesh.
Show all 11Show fewer
  • Pregnancy
  • Abuse of psychoactive substances.
  • Daily consumption of opioids.
  • Consumption of analgesics during the last 24 hours prior to surgery.
  • Infection at the incision site

Trial locations and contacts

2 sites in 1 country.

Patricia Salazar Villegas, Mg. contact

(57) 6 8781500 ext. 11644

patricia.salazar@ucaldas.edu.co

Juan C Gómez Salgado, Specialist contact

(57) 6 8783060 ext. 11158

juan.gomez@ucaldas.edu.co

Colombia2 sites
  • Hospital Departamental Universitario Santa Sofía de Caldas

    Manizales, Caldas Department, 170001

    Juan C Gómez Salgado, Specialist, (57) 6 8879200, juan.gomez@ucaldas.edu.co

  • SES Hospital de Caldas

    Manizales, Caldas Department, 170001

    Oscar D Aguirre Ospina, Specialist, (57) (6) 8782500, oscardavid.celta@gmail.com

    Juan C Gómez Salgado, Specialist

Other trials in Colombia

About this study

Acute postoperative pain is one of the most important centers of therapeutic attention in postoperative phase of any procedure. It is a complex entity that requires a multiple intervention to be treated and, depending on the intervened surgical site, it has different approaches.

Despite attempts to reduce postoperative pain by implementing management protocols, rates of pain prevalence from moderate acute to severe pain are still reported as high as 50% in the first 24 postoperative hours. Among the surgeries that report greater intensity of postoperative pain is open inguinal Herniorrhaphy. That is why several techniques have been described for the management of acute pain in this surgery postoperative, among which PAT blocking has shown to be beneficial in some studies. However, some reports question its usefulness but with the emergence of ultrasound-guided techniques for its realization, interest in this blockage has grown back.

This study aims to demonstrate the utility of the PAT blocking in the management of acute pain of pre-peritoneal inguinal herniorrhaphy with mesh.

Read the detailed description
  1. Patient registry:

The cases will be recorded by an external agent who will verify compliance with the protocol by the treating physicians (surgeons and anesthesiologists); additionally this agent will interview patients for the processing of the instrument and will also collect the proper information of the procedure. At random and in an unannounced way, visits will be made to the centers of attention to verify that the procedure was done according to what had been agreed.

Additionally when the full record of the patients is registered in a database, they will be called one by one to confirm the information collected. Further records are sought in the systematized medical history in order to verify additional information.

  1. Quality assurance plan: i. Each record will be completed by an external agent to the surgical procedure who will be trained for this work according to the methodological design of the study. ii. Regular visits are made to the information collection site to confirm compliance with attention and randomization protocols. iii. Information collected on the instrument will be confirmed with each patient's the clinical history.
  2. Data verification for range and consistency: i. Each of the instruments for each unit of analysis will be typed in a database by the same person (who will be trained in the methodological design of the study) who will monitor that each variable has been collected according to the categories previously established for that variable. ii. One second revision of the database will be carried out by one of the researchers who will review column by column categories, so that they are consistent with the predefined rules for that range: Additionally, compatibility between these categories and other categories of variables that must be compatible will be verified. For example, the hour of completion of surgery is later than the start time, etc.
  3. Verification of data for Accuracy, Completeness and Representativeness i. Each instrument collected will be verified, with surgical description carried out by the surgeon, anesthesia report made by the anesthesiologist and medical developments made by the hospital physician in charge of patient care in the postoperative period. In case of finding any inconsistency, the confirmation of the information will proceed through an additional call to the patient and the treating specialists if necessary. ii. Record of the patient's inclusion in the protocol of the clinical trial, guiding the treating physicians in the active pursuit of the variables under study, will be included in all electronic medical records.
  4. Data Dictionary:
  • Consecutive: Unique number for each unit of analysis. Source: Patient. Code: Does not apply. Ranges: 1, 2, 3, 4, 5, and so on. Type: Organization.
  • Date: Day, month and year in which the surgery is carried out. Source: Medical history. Code: Does not apply. Ranges: Day: 1 a 31. Month: 1 a 12, Year: 2015. Type: Organization.
  • Age: Age at time of surgery. Source: Identification Number. Code: Does not apply. Ranges: 18, 19, 20, and so on. Type: Base.
  • Sex: Gender. Source: Patient. Code: Does not apply. Ranges: Male, Female. Type: Base.
  • Social Stratum: Economic level. Source: Patient. Code: Does not apply. Ranges: 1, 2, 3, 4, 5, 6. Type: Base.
  • Education: Educational level. Source: Patient. Code: Does not apply. Ranges: None, Primary School, Secondary School, technical, technological, professional, specialist, Master's, Doctoral degree. Type: Base.
  • Laterality: Side of hernia. Source: Patient. Code: Does not apply. Ranges: Right, Left. Type: Base.
  • ASA: Surgical risk. Source: Medical history. Code: Does not apply. Ranges: 1, 2, 3, 4, 5. Type: Clinic.
  • Weight: Weight in kilograms. Source: Medical history. Code: Does not apply. Ranges: 30, 31, 32, and so on. Type: Base.
  • Height: Height in meters. Source: Medical history. Code: Does not apply. Ranges: 1.4, 1.41, 1,42, and so on. Type: Base.
  • Background: Diseases that the patient has. Source: Medical history and patient. Code: Does not apply. Ranges: Asthma, chronic obstructive pulmonary disease (COPD), hypertension, diabetes, heart failure, etc. Type: Clinic.
  • Lockout duration: Block performance time (minutes). Source: Surgery room. Code: Does not apply. Ranges: 2, 3, 4, 5, and so on. Type: Anesthetic.
  • Duration of surgery: Surgery completion time (minutes). Source: Surgery room. Code: Does not apply. Ranges: 15, 16, 17, and so on. Type: Surgical.
  • Adverse Reactions: Side effects and complications. Source: Surgery room. Code: Does not apply. Ranges: Hypotension, bradycardia, arrhythmias, aspiration of blood, viscera perforation, hematoma, femoral nerve block, infiltration resistance. Type: Primary result.
  • Realization: Specialist who performed the lock. Source: Surgery room. Code: Does not apply. Ranges: 1, 2. Type: Anesthetic.
  • Pain 1: Visual Analog Scale (VAS) when anesthetic medication suspended. Source: Patient. Code: Does not apply. Ranges: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Type: Primary result.
  • Rescue 1: Number of rescue doses of morphine applied early after anesthetics have been suspended. Source: Recovery nurse. Code: Does not apply. Ranges: 1, 2, 3, 4, and so on. Type: Secondary result.
  • Adverse effect 1: Adverse effect presented early after anesthetics is suspended. Source: Recovery nurse. Code: Does not apply. Ranges: Vomiting, nausea, itching, dry mouth, drowsiness, respiratory depression, none, other. Type: Secondary result.
  • Pain 2: VAS 24 hours after anesthetic medication is suspended. Source: Patient. Code: Does not apply. Ranges: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. Type: Primary result.
  • Rescue 2: Number of rescue tramadol dosage applied between the first hour and 24-hour after anesthetic is suspended. Source: Patient. Code: Does not apply. Ranges: 1, 2, 3, 4, and so on. Type: Secondary result.
  • Adverse effect 2: Adverse effect occurred between first hour and 24-hours after anesthetic is suspended. Source: Patient. Code: Does not apply. Ranges: Vomiting, nausea, itching, dry mouth, drowsiness, respiratory depression, none, other. Type: Secondary result.
  • Intervention: Application of local PAT anesthetic. Source: Currency format (Randomization). Code: Does not apply. Ranges: Yes (Intervention), No (Placebo). Type: Intervention.
  1. Standard Operation Procedures: i. Registration operation:
  2. Patient Recruitment:
  3. All patients scheduled for inguinal herniorrhaphy by the surgeon, will be reported by the administrative programming group to the researchers who will attend the preoperative evaluation by anesthesiology to practice informed consent and inclusion and exclusion criteria. Patients that can continue with the protocol will be included in the study.
  4. The day of the surgery the surgical instrumentation group will perform the patients' randomization with a consecutive (identification number) and, without knowing the patient, will take to the operating room the substance to apply in the PAT.
  5. Data collection:
  6. During surgery a research assistant who is blind to the applied substance, shall record the data collection instrument based on what he observes in the operating room and on what he questions in the first hour after the suspension of anesthetics in the post-anesthesia care room.
  7. After 24 hours of suspending the anesthetic, the research assistant will call the patient to question him about the necessary information to complete the data collection instrument of.
  8. Data management:
  9. The missing information in the database will be completed through review of medical records, interview with the surgeon, anesthesiologist and unit post-anesthesia care nurse. The information still needed, will be supplemented through a call to the patient. If despite the above it is not possible to get the required information, the case will be withdrawn for further analysis by intention to treat.
  10. Visits, audits and random checks to confirm the effectiveness of the data collection will be made. ii. Analysis Activities: <!-- -->
  11. Data analysis: Information of the instruments will be typed for the development of a database which will be complemented by the intervention variable the day determined to collect the sample. After that it will be delivered to the researchers who will undertake the analysis and interpretation so that later they can make the socialization of results.
  12. Adverse effects report: Whenever an adverse outcome is evidenced, it will be reported to the researchers and treating physicians (surgeon and anesthesiologist). Additionally the patient will be informed. Likewise it will be notified on clinical trial data base.
  13. Change management:
  14. If it is necessary to make a change to the protocol or data collection, researchers will meet to discuss the best option which does not affect the overall outcome of the investigation, but also which does not put in an additional hazard the patients' safety. When this aspect is defined a statement to the entire group of research will be issued.
  15. If a severe and frequent adverse reaction occurs, the possibility to suspend the controlled clinical trial will be determined between the researchers and the medical ethics committee.
  16. Evaluation of the sample size:
  17. Number of participants: The sample size was calculated using the formula for mean difference in analytical studies with a confidence index of 95%, a margin of error of 5%, a statistical power of 80%, a variance of 10% and a minimum differential detection value of 2.8%, compared to which a sample of 40 patients was obtained. With a loss rate of 10% the sample size was expanded to 44 patients. ii. Years participated: Since it is an acute pain study 24 hours were determined to monitor.
  18. Missing data plan:
  19. Missing data will be completed with clinical history, interview o professionals involved with patient care, calls and / or visits to patients. If data loss remains an analysis by intention to treat will proceed.
  20. Statistic analysis plan: i. Frequency distribution and qualitative variables association tables will be made, statistical significance for p values less than 0.05 will be determined, association between intervention variable and primary outcome and secondary outcome variables will be sought using for t his purpose the statistics analysis plan.
Being tested
TAP block with Bupivacaine at 0.25%, Placebo saline solution
Keywords
Hernia, Inguinal, Herniorrhaphy, Abdominal Wall, Analgesia, Pain, Postoperative
Medical subject headings
Pain, Postoperative, Hernia, Inguinal, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TAP block with Bupivacaine at 0.25%Drug

    Also called TAP block, Infiltration of local anesthetic, Local anesthesia in inguinal herniorrhaphy

    Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.

  • Placebo saline solutionDrug

    Also called Saline solution

    Application of 20 mL of saline solution in the transverse abdominis plane (TAP).

Study groups in NCT02299908
Study groupRoleWhat they receive
TAP block with Bupivacaine at 0.25%ExperimentalIntervention: Injection of local anesthetics in the transverses abdominal plane
Receives: Drug: TAP block with Bupivacaine at 0.25%
Placebo saline solutionPlacebo comparatorPlacebo: Injection of saline solution in the transverses abdominal plane
Receives: Drug: Placebo saline solution

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postoperative acute pain measured by the visual analog scale (VAS) from 1-10 with 1 being the lowest and 10 the highest intensity after one hour of anesthesia suspension.

    Measured: 1 hour after the suspension of anesthesia

Secondary outcomes (5)
  1. Opioid Consumption 1

    Number of rescue doses of 2 mg of Morphine each one, used for pain management in the first hour after stopping the administration of anesthetic agents

    Measured: 1 hour after the suspension of anesthesia

  2. Adverse reactions 1

    Adverse reactions present in the first hour after the suspension of anesthesia

    Measured: 1 hour after the suspension of anesthesia

  3. Postoperative acute pain 2

    Measured: 24 hours after the suspension of anesthesia

  4. Adverse reactions 2

    Measured: 24 hours after the suspension of anesthesia

  5. Opioid Consumption 2

    Measured: 24 hours after the suspension of anesthesia

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Nov 2014 (estimated)
  2. Study startNov 2014
  3. Primary completionJul 2015 (estimated)
  4. Study completionOct 2015 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02299908
Sponsor's protocol ID
VIP 1691514
Status last verified
Nov 2014
First submitted
17 Nov 2014
Last updated
24 Nov 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing TAP block with Bupivacaine at 0.25% in people with Pain, Postoperative, run by Patricia Salazar Villegas at 2 sites in Colombia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Nov 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Patricia Salazar Villegas, Mg. ((57) 6 8781500 ext. 11644, patricia.salazar@ucaldas.edu.co), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postoperative acute pain measured by the visual analog scale (VAS) from 1-10 with 1 being the lowest and 10 the highest intensity after one hour of anesthesia suspension. (time frame: 1 hour after the suspension of anesthesia). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Nov 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in